Advertisement

Virchows Archiv

, 455:485 | Cite as

Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers

  • Jung Ho Kim
  • So Hyun Shin
  • Hyeong Ju Kwon
  • Nam Yun Cho
  • Gyeong Hoon KangEmail author
Original Article

Abstract

CpG island methylator phenotype (CIMP) refers to a subset of colorectal cancers (CRCs) that are characterized by concordant hypermethylation of multiple CpG island loci. CIMP+ CRCs have peculiar clinicopathological features. However, controversy exists over prognostic implications of CIMP in CRCs. We analyzed 320 cases of CRCs for their CIMP status using the MethyLight assay and determined clinicopathological features and prognostic implications of CIMP alone or in combination with microsatellite instability (MSI). With methylation of five or more markers among eight markers examined, CIMP+ tumors were significantly associated with female gender, proximal tumor location, poor differentiation, nodal metastasis, more advanced cancer, BRAF mutations, MSI, and poor prognosis (all P values <0.05). Ogino’s combined eight-marker panel outperformed the Ogino and the Laird five-marker panels in detecting these features. Of the four molecular subtypes generated by the combination of CIMP and MSI status, the CIMP+/MSI− subtype showed the worst clinical outcome (P = 0.0003). However, poor prognosis of CIMP+/MSI− subtype was found to be attributed to BRAF mutation. In conclusion, the CIMP+/MSI− subtype tends to present with distinct clinicopathological and molecular features and shows the worst clinical outcome among the four molecular subtypes of CRCs.

Keywords

Colon cancer CpG island methylator phenotype DNA methylation Microsatellite instability 

Notes

Acknowledgments

This study was supported by the 21C Frontier Functional Human Genome Project from the Ministry of Science & Technology in Korea (FG09-11-02) and by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0720540).

Conflict of interest statement

We declare that we have no conflict of interest.

Supplementary material

428_2009_857_MOESM1_ESM.doc (43 kb)
Supplementary Table 1 (DOC 43 kb)
428_2009_857_MOESM2_ESM.doc (58 kb)
Supplementary Table 2 (DOC 58.5 kb)

References

  1. 1.
    Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196CrossRefPubMedGoogle Scholar
  2. 2.
    Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMedGoogle Scholar
  3. 3.
    Bird AP, Wolffe AP (1999) Methylation-induced repression—belts, braces, and chromatin. Cell 99:451–454CrossRefPubMedGoogle Scholar
  4. 4.
    Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113CrossRefPubMedGoogle Scholar
  5. 5.
    Schuebel KE, Chen W, Cope L et al (2007) Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 3:1709–1723CrossRefPubMedGoogle Scholar
  6. 6.
    Toyota M, Ahuja N, Ohe-Toyota M et al (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681–8686CrossRefPubMedGoogle Scholar
  7. 7.
    Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787–793CrossRefPubMedGoogle Scholar
  8. 8.
    Ogino S, Cantor M, Kawasaki T et al (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000–1006CrossRefPubMedGoogle Scholar
  9. 9.
    Nagasaka T, Koi M, Kloor M et al (2008) Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 134:1950–1960.e1CrossRefPubMedGoogle Scholar
  10. 10.
    Shen L, Toyota M, Kondo Y et al (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 104:18654–18659CrossRefPubMedGoogle Scholar
  11. 11.
    Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH (2008) CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 132:1657–1665PubMedGoogle Scholar
  12. 12.
    Ward RL, Cheong K, Ku SL et al (2003) Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21:3729–3736CrossRefPubMedGoogle Scholar
  13. 13.
    Shen L, Catalano PJ, Benson AB 3rd et al (2007) Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 13:6093–6098CrossRefPubMedGoogle Scholar
  14. 14.
    Barault L, Charon-Barra C, Jooste V et al (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68:8541–8546CrossRefPubMedGoogle Scholar
  15. 15.
    Samowitz WS, Sweeney C, Herrick J et al (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063–6069CrossRefPubMedGoogle Scholar
  16. 16.
    Ogino S, Goel A (2008) Molecular classification and correlates in colorectal cancer. J Mol Diagnostics 10:13–27CrossRefGoogle Scholar
  17. 17.
    Yoo EJ, Park SY, Cho NY et al (2008) Helicobacter pylori-infection-associated CpG island hypermethylation in the stomach and its possible association with polycomb repressive marks. Virchows Arch 452:515–524CrossRefPubMedGoogle Scholar
  18. 18.
    Kang GH, Lee S, Cho NY et al (2008) DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88:161–170CrossRefPubMedGoogle Scholar
  19. 19.
    Weisenberger DJ, Campan M, Long TI et al (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33:6823–6836CrossRefPubMedGoogle Scholar
  20. 20.
    Lee S, Cho NY, Choi M et al (2008) Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 58:104–113CrossRefPubMedGoogle Scholar
  21. 21.
    Ogino S, Kawasaki T, Kirkner GJ et al (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagnostics 9:305–314CrossRefGoogle Scholar
  22. 22.
    Georgiades IB, Curtis LJ, Morris RM, Bird CC, Wyllie AH (1999) Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 18:7933–7940CrossRefPubMedGoogle Scholar
  23. 23.
    Goel A, Arnold CN, Niedzwiecki D et al (2003) Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 63:1608–1614PubMedGoogle Scholar
  24. 24.
    Cheng YW, Pincas H, Bacolod MD et al (2008) CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res 14:6005–6013CrossRefPubMedGoogle Scholar
  25. 25.
    Goel A, Nagasaka T, Arnold CN et al (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132:127–138CrossRefPubMedGoogle Scholar
  26. 26.
    Ogino S, Nosho K, Kirkner GJ et al (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90–96CrossRefPubMedGoogle Scholar
  27. 27.
    Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95:6870–6875CrossRefPubMedGoogle Scholar
  28. 28.
    Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P (2000) Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 156:1773–1779PubMedGoogle Scholar
  29. 29.
    Cunningham JM, Christensen ER, Tester DJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455–3460PubMedGoogle Scholar
  30. 30.
    Cunningham JM, Kim CY, Christensen ER et al (2001) The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780–790CrossRefPubMedGoogle Scholar
  31. 31.
    Yuen ST, Davies H, Chan TL et al (2002) Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451–6455PubMedGoogle Scholar
  32. 32.
    Chang SC, Lin JK, Yang SH et al (2006) Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 118:1721–1727CrossRefPubMedGoogle Scholar
  33. 33.
    Nagasaka T, Sasamoto H, Notohara K et al (2004) Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584–4594CrossRefPubMedGoogle Scholar
  34. 34.
    Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533CrossRefPubMedGoogle Scholar
  35. 35.
    Vilkin A, Niv Y, Nagasaka T et al (2009) Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer 115:760–769CrossRefPubMedGoogle Scholar
  36. 36.
    Young J, Barker MA, Simms LA et al (2005) Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 3:254–263CrossRefPubMedGoogle Scholar
  37. 37.
    Samowitz WS, Slattery ML, Sweeney C et al (2007) APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res 5:165–170CrossRefPubMedGoogle Scholar
  38. 38.
    Tanaka H, Deng G, Matsuzaki K et al (2006) BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 118:2765–2771CrossRefPubMedGoogle Scholar
  39. 39.
    Rajagopalan H, Bardelli A, Lengauer C et al (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934CrossRefPubMedGoogle Scholar
  40. 40.
    Oliveira C, Pinto M, Duval A et al (2003) BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22:9192–9196CrossRefPubMedGoogle Scholar
  41. 41.
    Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagnostics 8:582–588CrossRefGoogle Scholar
  42. 42.
    Rashid A, Shen L, Morris JS, Issa JP, Hamilton SR (2001) CpG island methylation in colorectal adenomas. Am J Pathol 159:1129–1135PubMedGoogle Scholar
  43. 43.
    Jass JR, Baker K, Zlobec I et al (2006) Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‘fusion’ pathway to colorectal cancer. Histopathology 49:121–131CrossRefPubMedGoogle Scholar
  44. 44.
    Kakar S, Deng G, Cun L, Sahai V, Kim YS (2008) CpG island methylation is frequently present in tubulovillous and villous adenomas and correlates with size, site, and villous component. Hum Pathol 39:30–36CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Jung Ho Kim
    • 1
  • So Hyun Shin
    • 2
  • Hyeong Ju Kwon
    • 1
  • Nam Yun Cho
    • 2
  • Gyeong Hoon Kang
    • 1
    • 2
    Email author
  1. 1.Department of PathologySeoul National University College of MedicineSeoulSouth Korea
  2. 2.Laboratory of Epigenetics, Cancer Research Institute and 2nd Stage Brain KoreaSeoul National University College of MedicineSeoulSouth Korea

Personalised recommendations